EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)-Reference-Cited by-同舟云学术

EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)

Published:2020-04-27 Issue:2 Volume:58 Page:214-224
ISSN:1995-4492
Container-title:Rheumatology Science and Practice
language:
Short-container-title:Naučno-praktičeskaâ revmatologiâ

Author:

Nasonov E. L.¹^ORCID,Avdeeva A. S.²^ORCID,Lila A. M.³^ORCID

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

2. V.A. Nasonova Research Institute of Rheumatology

3. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Publisher

Mediar Press

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference260 articles.

1. Korsakova YuL, Korotaeva TV. Modern pharmacotherapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):75-82. doi: 10.14412/1995-4484-2019-75-82 (In Russ.)

2. James JA, Guthridge JM, Chen H, et al. Unique Sjö gren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2019 Sep 8. pii: kez335. doi: 10.1093/rheumatology/kez335

3. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201

4. Denton CO, Khanna D. Systemic sclerosis. Lancet. 2017;390:1658-99. doi: 10.1016/S0140-6736(17)30933-9

5. Paik J, Deeks ED. Tofacitinib: A review in psoriatic arthritis. Drugs. 2019;79(6):655-63. doi: 10.1007/s40265-019-01091-3

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of tofacitinib in psoriatic arthritis: literature review and case report;Meditsinskiy sovet = Medical Council;2023-11-23

2. Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022;Rheumatology Science and Practice;2023-06-28

3. Immuno-mediated comorbidity: clinical and pathogenetic aspects of the inﬂ ammatory bowel diseases and spondyloarthritis association;Experimental and Clinical Gastroenterology;2022-10-04

4. Janus kinase inhibitors in immunoinflammatory rheumatic diseases;Terapevticheskii arkhiv;2022-06-17

5. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology;Rheumatology Science and Practice;2022-05-13